PKM2 coordinates glycolysis and glutaminolysis in cancer cells

PKM2 协调癌细胞中的糖酵解和谷氨酰胺分解

基本信息

  • 批准号:
    8788258
  • 负责人:
  • 金额:
    $ 16.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-01-01 至 2016-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): It is well documented that oncogenic products and growth signals alter metabolism of cancer cells. However, it is less well understood whether and how the metabolism adjustments of tumor cells feedback to affect tumor progression. It is also not well understood how cancer cells coordinate the alterations between two major metabolism pathways, glycolysis and glutaminolysis. We observed that that PKM2 localized to the cell nucleus. The nuclear PKM2 functions as a transcription co-activator to activate the gene transcription. More importantly, PKM2, a key glycolysis enzyme, functions as a protein kinase to phosphorylate stat3 at Y705 therefore activating gene transcription. Our experiments demonstrate that the protein kinase activity of PKM2 mediates the effects of PKM2 in promoting cell proliferation. In addition, our study revealed that PKM2 upregulates glutaminase expression, indicating a feedback loop between cancer cell metabolism and cell proliferation, and potential function of this glycolysis enzyme in coordinating the changes of both glycolysis and glutaminolysis. The goal of this proposed research project is to understand the role of PKM2 in tumor progression. We propose three specific aims to test our hypothesis that PKM2, a glycolysis enzyme, facilitates cell proliferation and tumor progression not only by adjusting glycolytic metabolites flow in favor of biosynthesis, but also by regulating the glutaminolysis. By acting at multiple different metabolism processes, PKM2 fulfill the role of coordinating metabolism alterations and cell proliferation during tumor progression. The experiments proposed in this project will first test whether PKM2 indeed activates glutaminolysis. Experiments proposed in the 2nd specific aim will address whether activation of glutaminolysis by PKM2 also occurs in vivo. In the specific aim 3, we will elucidate how the growth signals affect the function of PKM2 in activation of glutaminolysis. Our studies will ultimately be applied to the development of new strategies for cancer treatment.
描述(由申请人提供):有充分的文献证明致癌产物和生长信号改变癌细胞的代谢。然而,人们对肿瘤细胞的代谢调节是否以及如何反馈影响肿瘤进展知之甚少。癌细胞如何协调糖酵解和谷氨酰胺解这两种主要代谢途径之间的变化,也不是很清楚。我们观察到PKM2定位于细胞核。核PKM2作为转录共激活因子激活基因转录。更重要的是,PKM2,一个关键的糖酵解酶,作为一个蛋白激酶磷酸化stat3在Y705,从而激活基因转录。我们的实验证明PKM2的蛋白激酶活性介导PKM2促进细胞增殖的作用。此外,我们的研究发现PKM2上调谷氨酰胺酶的表达,表明癌细胞代谢和细胞增殖之间存在反馈回路,并且该糖酵解酶在协调糖酵解和谷氨酰胺酶的变化方面具有潜在的功能。本研究项目的目标是了解PKM2在肿瘤进展中的作用。我们提出了三个特定的目标来验证我们的假设,即PKM2,一种糖酵解酶,不仅通过调节糖酵解代谢产物的流动,有利于生物合成,而且通过调节谷氨酰胺水解,促进细胞增殖和肿瘤进展。通过

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhi-Ren Liu其他文献

Zhi-Ren Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhi-Ren Liu', 18)}}的其他基金

A treatment drug for triple negative breast cancer
一种治疗三阴性乳腺癌的药物
  • 批准号:
    10643890
  • 财政年份:
    2022
  • 资助金额:
    $ 16.1万
  • 项目类别:
A treatment drug for triple negative breast cancer
一种治疗三阴性乳腺癌的药物
  • 批准号:
    10483825
  • 财政年份:
    2022
  • 资助金额:
    $ 16.1万
  • 项目类别:
Development of a protein drug for pancreatic cancer treatment
开发治疗胰腺癌的蛋白质药物
  • 批准号:
    10551992
  • 财政年份:
    2017
  • 资助金额:
    $ 16.1万
  • 项目类别:
Development of a protein drug for pancreatic cancer treatment
开发治疗胰腺癌的蛋白质药物
  • 批准号:
    10250688
  • 财政年份:
    2017
  • 资助金额:
    $ 16.1万
  • 项目类别:
Development of a protein drug for pancreatic cancer treatment
开发治疗胰腺癌的蛋白质药物
  • 批准号:
    9765276
  • 财政年份:
    2017
  • 资助金额:
    $ 16.1万
  • 项目类别:
Development of anti-angiogenesis therapy targeting integrin
针对整合素的抗血管生成疗法的开发
  • 批准号:
    9023506
  • 财政年份:
    2014
  • 资助金额:
    $ 16.1万
  • 项目类别:
Development of anti-angiogenesis therapy targeting integrin
针对整合素的抗血管生成疗法的开发
  • 批准号:
    8631535
  • 财政年份:
    2014
  • 资助金额:
    $ 16.1万
  • 项目类别:
PKM2 coordinates glycolysis and glutaminolysis in cancer cells
PKM2 协调癌细胞中的糖酵解和谷氨酰胺分解
  • 批准号:
    8621210
  • 财政年份:
    2014
  • 资助金额:
    $ 16.1万
  • 项目类别:
Functional role of p68 tyrosine phosphorylation in cancer metastasis
p68 酪氨酸磷酸化在癌症转移中的功能作用
  • 批准号:
    7487547
  • 财政年份:
    2007
  • 资助金额:
    $ 16.1万
  • 项目类别:
P68 and Ca-calmodulin interaction in cell migration
P68 和 Ca-钙调蛋白在细胞迁移中的相互作用
  • 批准号:
    8693188
  • 财政年份:
    2007
  • 资助金额:
    $ 16.1万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了